Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells

Anna Wenger*, Katja Werlenius†,‡, Alexander Hallner§, Fredrik Bergh Thorén§, Dan Farahmand†,¶, Magnus Tisell§,¶, Anja Smits#,**, Bertil Rydenhag†,¶, Asgeir S. Jakola†,¶,†† and Helena Carén*

*Sahlgrenska Cancer Center, Department of Pathology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden; †Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; ‡Sahlgrenska Cancer Center, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden; §TIMM laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden; ¶Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden; ‡Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; **Department of Neuroscience, Neurology, Uppsala University, University Hospital, Uppsala, Sweden; ††Department of Neurosurgery, St. Olavs University Hospital, Trondheim, Norway

Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of less than 15 months, emphasizing the need for better treatments. Immunotherapy as a treatment for improving or aiding the patient’s own immune defense to target the tumor has been suggested for GBM. A randomized clinical trial of adoptive cell transfer using ALECSAT (Autologous Lymphoid Effector Cells Specific Against Tumor Cells) is currently ongoing in Sweden. Here we performed a paired pre-clinical study to investigate the composition and in vitro effect of ALECSAT and identify determinants for the effect using autologous GBM-derived cancer stem cells (CSC), immunocytochemistry and flow cytometry. We show a clear dose-response relationship of ALECSAT on CSC, suggesting that the number of infused cells is of importance. In addition, the in vitro effect of ALECSAT on CSC correlated significantly to the blood count of T helper (Th) cells in the patient indicating a potential benefit of collecting cells for ALECSAT preparation at an even earlier stage when patients generally have a better blood count. The factors identified in this study will be important to consider in the design of future immunotherapy trials to achieve prolonged survival.

Neoplasia (2018) 20, 25–31

Introduction
Glioblastoma (GBM), a type of high-grade glioma (HGG), is the most common malignant brain tumor in adults with a very poor prognosis [1–3]. The median survival is less than 15 months despite multimodal treatment with maximal safe surgical tumor resection followed by the so called Stupp regimen comprising radiotherapy and concomitant and adjuvant chemotherapeutic treatment with the alkylating agent temozolomide (TMZ) [4,5]. New and better treatments to improve the prognosis are needed and immunotherapy,
which incorporates different methods to induce, boost or restore the immune system of the patient, has been suggested for GBM and several clinical trials are currently ongoing [6]. The rationale for employing immunotherapy for GBM is supported by the association between elevated number of infiltrating T cells in GBM tumors and a better prognosis [7]. Further, infusion of CD8+ cytotoxic T lymphocytes (CTL) and CD4+ T helper (T_h) cells into mice with brain tumors prolonged the survival [8]. However, GBM tumors display numerous immunoevasive features to avoid elimination [9], such as immune suppression by T regulatory (T_reg) cells [10,11], decreased expression of major histocompatibility complex (MHC), and a general low immunogenicity [12]. Another issue is quiescent/non-proliferating cells such as cancer stem cells (CSC), which are thought to be among the drivers behind tumor recurrence in GBM and are therefore of particular importance to target during treatment [13,14]. In vitro studies have demonstrated that activated natural killer (NK) cells, i.e. cytotoxic lymphocytes which unlike CTL are not antigen-specific, are highly effective against CSC derived from GBM [15] and that NK cells preferentially target CSC [16].

The efficacy and safety of an immunotherapy treatment called ALECSAT (Autologous Lymphoid Effector Cells Specific Against Tumor Cells) is investigated as an add-on therapy to radiotherapy and TMZ in newly diagnosed GBM in an ongoing clinical randomized phase II multi-center trial in Sweden (clinical trial identifier; NCT-02799238). ALECSAT is based on the type of immunotherapy known as adoptive cell transfer where, in this case, autologous cytotoxic NK cells and CTL are amplified and activated ex vivo from a blood sample prior to injection. Given the relatively few published studies on immune-mediated eradication of CSC in an autologous setting, we performed a parallel pre-clinical study to examine the effect of ALECSAT on autologous GBM-derived CSC in vitro. The aim was to identify potentially adjustable parameters affecting the in vitro effect of ALECSAT that may be of clinical relevance. In this study we describe several key factors to consider in future immuno-therapy studies to optimize study design and eventually achieve prolonged patient survival.

## Materials and Methods

### Tumor Collection and Cell Culture

Fresh tissue from tumors was collected from the patients’ tumor resection at Sahlgrenska University Hospital after informed consent from the patients. The tumor tissue was dissociated and cells were cultured as described previously [17] up to at least passage five prior to in vitro ALECSAT treatments. All CSC lines were derived from the primary tumor except GU-HGG-160, which was established from the recurring tumor. As non-cancer cells controls, we used adult stem-like cells, GU-NS-6, derived from human ependyma from a patient undergoing endoscopic surgery for a brain cyst after signed informed consent and the cells were cultured on laminin in neural stem cell media supplemented with 10% fetal bovine serum (FBS). In addition, BJ cells (human fibroblasts) (ATCC) cultured in Minimum Essential medium (Life Technologies) supplemented with 10% FBS and split every 2 to 4 days using Trypsin-EDTA were used.

**ALECSAT Production**

ALECSAT was developed and produced by CytoVac A/S (Hørsholm, Denmark) according to their patented technology (WO 2008081035 A1, Anti-tumor vaccine derived from normal chemically modified cells). Briefly, lymphocytes and monocytes were isolated from a peripheral blood sample from each patient and the monocytes were cultured and differentiated into dendritic cells. Autologous activated T_h cells were generated by co-culture of mature dendritic cells and lymphocytes. The T_h cells were employed as antigen presenting cells by inducing the expression of antigens, predominantly the cancer/testis antigens (CTA), in the cells through treatment with 5-aza-2’-deoxycytidine, a DNA-demethylation agent. Non-activated lymphocytes were then stimulated by the CTA-expressing activated T_h cells and the effector cells were expanded in number. Each dose of ALECSAT contained $10^7$ to $10^9$ cells and the production took 20 to 26 days.

### Clinical Treatment Schedule

The patients received standard treatment according to the Stupp regimen with ALECSAT as an add-on therapy; maximal safe tumor resection and blood donation for the first ALECSAT treatment followed by external radiotherapy (daily fractions of 2 Gy, 5 days per week up to a total dose of 60 Gy) and oral TMZ ($75$ mg/m$^2$) daily for approximately six weeks. The patients received the first ALECSAT treatment after completion of radiotherapy and simultaneously donated blood for the next treatment. After a 4- to 5-week break on completion of radiotherapy, patients received adjuvant TMZ treatment, typically six cycles ($150$-$200$ mg/m$^2$ daily for 5 days every 28 days), alongside three doses of ALECSAT at four week intervals followed by single doses approximately every three months.

### In vitro Cytotoxicity Assay Using ALECSAT

The day before ALECSAT treatment, 5 000 or 10 000 cells to be treated (CSC or control cells) were seeded in 96-well plates in triplicates for each condition. ALECSAT cells, provided by CytoVac A/S, were shipped at room temperature in growth media, centrifuged upon arrival, resuspended in culture media (for the cells to be treated) and counted with a Countess™ Automated Cell Counter (Invitrogen). ALECSAT cells were serially diluted to ratios ranging from 20 times more ALECSAT cells than seeded GU-HGG cells (20:1) to ten times fewer ALECSAT cells compared to seeded GU-HGG cells (1:10). Half of the media was removed from the cells in the 96-well plates and replaced with media containing ALECSAT at varying ratios with triplicates for each condition, and 5μM EdU (Invitrogen) when proliferation was assessed. Treated cells were fixed with 4% paraformaldehyde after 24 hours ALECSAT treatment. Surplus of ALECSAT was frozen in CellBanker (Amsbio) with 20% FBS for flow cytometry analysis at a later time point.

### Immunostaining, Quantification and Measures

Fixed cells were permeabilized with triton-x and, if applicable, treated according to the manufacturer’s instructions to expose EdU staining. Primary antibodies (mouse monoclonal Nestin, R&D MAB1259, 1:500; rabbit SOX2, Abcam ab97795; 1:1000; rabbit vimentin, Abcam ab45939, 1:900), were added after a blocking step and incubated overnight at 4°C. Secondary antibodies, goat, conjugated to Alexa dyes (Molecular Probes), 1:1000, were left on for one hour at room temperature. Finally, cell nuclei were stained with DAPI (Sigma Aldrich). Plates were scanned with the Operetta (Perkin Elmer) and analyzed with the Harmony software. The number of cells was automatically counted with triplicates for each condition. Error bars in the graphs denote standard deviation. The effect of ALECSAT was estimated as the slope of the linear region of...
the dose response curve (logarithmic x-axis) for each treatment. P values are included where appropriate and $P < .05$ was considered significant. The Bonferroni correction was used to adjust for multiple testing. Pearson correlation ($r$) was calculated for correlations.

**Flow Cytometry Analysis of ALECSAT and Blood Samples**

Frozen ALECSAT cells were thawed and washed in warm media prior to flow cytometry analysis. ALECSAT cells were stained with the following anti-human antibodies: CD3-PerCP-Cy5.5 (SK7), CD4-PE (SK3), CD8-APC (RPA-T8), CD16-APC-Cy7 (3G8) and CD56-PE-Cy7 (NCAM16.2) all from BD Biosciences. Samples were analyzed using a 4-laser BD LSRFortessa SORP (405, 488, 532 and 640 nm; BD Biosciences) and data was analyzed in FACSDiva Version 7 (BD Biosciences) or FlowJo version 10 (TreeStar).

**Results**

**Patient and Cell Line Information**

In this study we examined the *in vitro* effect of ALECSAT on autologous GBM-derived CSC cultured under serum-free conditions in stem cell media to retain the features of the tumor it was derived from [17]. We also performed flow cytometry analysis on the blood donated for production of ALECSAT and the final ALECSAT product (Figure 1A). All patients enrolled in the study were diagnosed with primary GBM (see Table 1 for patient data). The treatment protocol consisted of repeated doses of ALECSAT as add-on therapy to standard treatment (radiotherapy and TMZ; Figure 1B). We successfully derived CSC lines from seven of the first nine patients (78%) in the study for which tissue material was available. All CSC lines were verified by immunocytochemistry as proliferative (EdU incorporation) and positive for the stem cell markers Nestin and SOX2, and the neural progenitor marker Vimentin (Supplementary Figure S1). GU-NS-6 was proliferative, positive for Vimentin and had a heterogeneous expression of Nestin (Supplementary Figure S2).

**Analysis of ALECSAT Content with Flow Cytometry**

First, we characterized the content of ALECSAT products ($n = 19$) with flow cytometry. Principal component analysis (PCA) of these data revealed both inter- and intra-patient variation of the product infused to the patients, particularly regarding the percentage of CD3+

| Table 1. Patient Data |
|-----------------------|
| Patient ID | Gender | Age at Diagnosis (Years) | Diagnosis |
| GU-HGG-160 | M | 41 | Gliosarcoma |
| GU-HGG-131 | M | 57 | Glioblastoma |
| GU-HGG-145 | M | 56 | Glioblastoma |
| GU-HGG-151 | F | 44 | Glioblastoma |
| GU-HGG-150 | F | 40 | Glioblastoma |
| GU-HGG-163 | F | 68 | Glioblastoma |
| GU-HGG-178 | F | 49 | Glioblastoma |
T cells (range 21-87%; Figure 2A). As illustrated in Figure 2B, there was an inverse correlation between the proportion of NK cells and CTL cells in ALECSAT, indicating the presence of cytotoxic cells regardless of composition. The composition of a representative treatment of average lymphocyte proportions is displayed in Figure 2C.

Forto each case, we observed an increase in CD3+ (T cells), Th1 (CD3+4+), CTL (CD3+8+) and NK cells at later ALECSAT treatments compared to the first but there was no discernible overall trend (data not shown).

ALECSAT Displays Broad and Robust Cytotoxicity

Next, we investigated the effect of ALECSAT on autologous CSC and non-cancerous cells (adult neural stem-like cells; GU-NS-6 and fibroblasts; BJ) at the same effector/target ratios of ALECSAT. The CSC and both control cell lines displayed susceptibility to ALECSAT, demonstrating a broad cytotoxic effect of ALECSAT (Figure 3A). The BJ cells were more resistant than CSC to ALECSAT (Figure 3B). The cytotoxic effect on BJ cells varied between ALECSAT treatments and was significantly correlated ($r = 0.996, P = .05$) to the proportion of cytotoxic NK cells in the ALECSAT (data not shown). This was in contrast to the adult stem-like cells GU-NS-6, which were treated with ALECSAT containing very low levels of cytotoxic NK cells but high levels of CTL, suggesting that CTL could eliminate adult neural stem-like cells but not BJ cells. We also examined if ALECSAT affected the proliferation of CSC and found that ALECSAT decreased the proportion of proliferating cells among the surviving cells with increasing doses after 24 hours of treatment (Figure 3C).

**Figure 2.** Content of ALECSAT. (A) Principal component analysis (PCA) of the viability and content of ALECSAT treatments (n = 19) for the following cell types; CD3+ (T cells), CD3+4+ (T helper cells), CD3+8+ (cytotoxic T lymphocytes; CTL), CD3-56+ (bright NK cells) and CD3-16+56+ (cytotoxic NK cells). (B) The proportion of cytotoxic NK cells and CTL in ALECSAT are inversely correlated. Each dot represents one ALECSAT product. (C) Flow cytometry plot and gating of the content of one ALECSAT treatment of average composition.

**ALECSAT Eliminates Cancer Stem Cells in a Dose-Dependent Manner and the Effect Correlates to the Blood Count of T Helper Cells**

We noted that already after 24 hours ALECSAT mediated almost complete elimination of CSC at the higher ALECSAT to CSC ratios (Figure 4A). The susceptibility to the ALECSAT product varied between the CSC lines but also between the treatments for the same patient. Some treatments had no effect on the CSC, but the majority exhibited a dose-response relationship to increasing concentrations of ALECSAT (Figure 4B). The effect of ALECSAT was measured as the slope of the linear region of the dose-response curves for each treatment and was found to correlate significantly with the number of Th1 cells (CD3+4+) alone, the ratio of Th1/T cells, the ratio of CTL/T cells (inverse correlation) and Th1/CTL cells in the patient’s blood from which the ALECSAT was produced (Figure 4C and Table 2). There was no correlation between the effect of ALECSAT and the content of the ALECSAT treatments.

**Discussion**

The dismal prognosis of GBM signifies the dire need of new treatments. The diffuse and infiltrating nature of GBM complicates complete tumor resection and immunotherapy has been suggested as an attractive option to eradicate the remaining tumor cells as its cytotoxic effect is tumor specific. Immunotherapy in the form of NK cells has shown great promise of targeting CSC, which are believed to be one of the main culprits behind recurrence [13,14]. Several clinical
immunotherapy trials are currently ongoing, including ALECSAT NCT-02799238, which evaluates the effect of the immunotherapy ALECSAT as an add-on therapy to standard treatment for primary GBM. However, many questions regarding the optimal type of immunotherapy and the biological key factors affecting patient survival remain unanswered.

Our results show that ALECSAT has a robust and broad cytotoxic effect targeting GBM-derived CSC and the two tested control cell lines. In addition to the cytotoxic effect of ALECSAT, we also documented a decrease in proliferation of the surviving population of CSC. The highest doses investigated were very effective against CSC, achieving a complete response, which is encouraging given the resistance of these cells to conventional therapy [14]. Autologous NK cells have previously been described capable of completely eliminating GBM stem cells at ratios (20:1 or 40:1) [15] similar to those in our study (10:1 or 20:1). We observed a strong dose-response relationship of ALECSAT on CSC for the majority of the treatments, which is of potential clinical relevance as $10^7$ - $10^9$ ALECSAT cells are infused into the patient at each treatment. This is further supported by a study of melanoma in mice where an increasing number of injected T cells correlated significantly with larger tumor regression [18]. From this we hypothesize that patients infused with the highest amount of cells will have the greatest response. However, in order to obtain higher cell numbers, cells need to be cultured for a longer time ex vivo, which as a result may induce senescence [19,20] thus limiting the feasible cell number of quality cells for infusion. We conclude that further studies are needed to define the optimal amount of infused T cells in individual patients.

There was no significant correlation between the size of the lymphocyte populations in ALECSAT and its in vitro effect, suggesting that several cytotoxic mechanisms are involved. Considering the inverse correlation between NK and CTL cells in ALECSAT, it is tempting to speculate that both cell types can exert effector functions. We did find significant correlations between the in vitro effect of ALECSAT on CSC and the patients’ blood count (at the time of donation for ALECSAT production). These correlations particularly involved T<sub>h</sub> cells. Since there was no significant correlation between the number of CTL and the ALECSAT effect, the inverse correlation of CTL/T cells does not automatically imply that fewer CTL cells result in a worse effect. It is more likely that the inverse correlation of CTL/T cells reflects the significant correlation with T<sub>h</sub> cells, both in absolute numbers and as a ratio of T<sub>h</sub>/T cells, as the proportion of CTL must be low if the proportion of T<sub>h</sub> cells is high. These findings highlight the importance of T<sub>h</sub> cells, which have previously been shown necessary for the recruitment and cytolytic effect of CTL and to augment the effect of CTL [8,21–24]. However, for the majority of the patients we noted a trend of decreasing number of T<sub>h</sub> cells in the blood during treatment, as previously reported in a HGG study correlating low CD4 counts to shorter survival and also showing a toxic effect of TMZ and radiation on CD4+ cells [25,26]. The observed correlation between T<sub>h</sub> cell count in the blood and the in vitro effect of ALECSAT suggests a potential therapeutic benefit of further advancing the blood donations and injections to an even earlier stage during treatment.

In conclusion, we have shown that ALECSAT is highly effective against CSC in vitro and that there is a clear dose-response

**Figure 3.** Cytotoxicity of ALECSAT on a range of cell types. (A) The percentage of remaining cells after ALECSAT treatment, compared to untreated cells, of cancer stem cells (CSC) and a paired non-cancer cell line (BJ, fibroblasts, or GU-NS-6, adult neural stem-like cells) for the highest ALECSAT dose examined for each pair. (B) The BJ cells are more resistant than the CSC and a higher dose of ALECSAT is required to eliminate all BJ cells. * denote a significant difference (P < .05) in the response of CSC and BJ at the indicated concentration. (C) The proportion of proliferating cells decrease with increasing doses of ALECSAT. * denote significant differences (P < .05) between the control (untreated GU-HGG) and ALECSAT for each cell line.
Our data identify the number of infused cells as an important parameter for efficacy of ALECSAT that may potentially prolong patient survival. Our results further show that the number of Th cells in the patient’s blood, which correlate to the effect on the CSC, are of particular importance and suggest that optimal benefit from ALECSAT treatment could be obtained by advancing treatment to an earlier phase when blood values are generally better. These factors together will be of importance for the design of future immunotherapy trials.

**Figure 4.** *In vitro* dose response correlates to patient’s blood values at the time of donation for ALECSAT. (A) Example image of the effect of increasing amounts of ALECSAT on cancer stem cells (CSC). Cell nuclei are stained with DAPI (blue) and the scale bar is 100 μm. (B) The cell lines respond in a dose-dependent manner to increasing amounts of ALECSAT for most treatments. The x-axis is the 10-logarithm of the ALECSAT:CSC ratio (concentration). Each cell line is presented in a separate graph and the number of the ALECSAT treatment is indicated after the cell line. (C) The slope in the linear region of the dose response curves were extracted and they correlated significantly with the ratio of T helper/T cells (Th; CD3+4+) in the patients’ blood at the time of donation for ALECSAT.

**Table 2.** Correlation Between Blood Count and the *In vitro* Effect of ALECSAT on Cancer Stem Cells

| Cell Type | Correlation (r) | Adjusted P Value |
|-----------|-----------------|-----------------|
| T cells   | 0.418           | 1.000           |
| Th cells  | 0.710           | .050 *          |
| Th/T cells| 0.784           | .005 *          |
| CTL/T    | -0.742          | .015 *          |
| CTL      | -0.153          | 1.000           |
| Th/CTL   | 0.735           | .018 *          |

Pearson correlation between the blood count of immune cells at donation and the *in vitro* effect of ALECSAT on cancer stem cells (measured as the slope in the linear region of dose response curves). The P value was adjusted for multiple testing (n = 10) with the Bonferroni correction. * denotes significant correlations at significance <0.05. Th, T helper cells; CTL, cytotoxic T lymphocytes.

Our data identify the number of infused cells as an important parameter for efficacy of ALECSAT that may potentially prolong patient survival. Our results further show that the number of Th cells in the patient’s blood, which correlate to the effect on the CSC, are of particular importance and suggest that optimal benefit from ALECSAT treatment could be obtained by advancing treatment to an earlier phase when blood values are generally better. These factors together will be of importance for the design of future immunotherapy trials.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.neo.2017.10.006.
We thank CytoVac A/S for providing ALECSAT, and Christoffer
Acknowledgements
and The Health Medical Care Committee at Västra Götaland of
This work was supported by the Swedish Cancer Society, the Swedish
Funding
relevant guidelines and regulations.
Ethics Approval and Consent to Participate
The study was approved by the regional ethics committee (Dnr
604-12, 927-14, 1001-15) and was carried out in accordance with the
Declarations
Conflicts of interest: none.
References

[1] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Prados MD, and Wiestler OD (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131, 1, 803–820.

[2] Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Janzarik W, Hjelmeland AB, and Perez-Atayde AR (2016). Prognostic factors for glioblastoma patients—a clinical population-based study. Acta Neurol Scand 820, 350–359.

[3] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[4] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[5] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[6] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[7] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[8] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[9] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[10] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[11] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[12] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[13] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[14] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[15] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[16] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.

[17] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Brem S, Tishler SM, and Sheline GE (2017). Advances in radiotherapy with concomitant and adjuvant temozolomide for glioblastoma. Neuro-Oncology 19, 8, 1071–1094.